

# Digital AMR Conference Week

24–28 August 2020

5 days of insights and engagement | 13 high-level panels |  
9 campus sessions | 90+ speakers | virtual 1:1 meetings

Time	Monday 24 August	Tuesday 25 August	Wednesday 26 August	Thursday 27 August	Friday 28 August
Virtual PARTNERING >> All Day					
00:00–23:59 CEST	1:1 partnering meetings	1:1 partnering meetings	1:1 partnering meetings	1:1 partnering meetings	1:1 partnering meetings
Morning agenda >> Additional programme offers					
09:45–10:45 CEST	<b>BEAM Alliance meet-up</b> Breakout sessions	<b>Expert campus</b> How to acceler- ate AMR drug development	<b>Expert campus</b> Focus on tuberculosis	<b>Start-up campus</b> Live pitches with jury voting	<b>Expert campus</b> Focus on vaccine devel- opment
11:00–12:30 CEST	<b>Expert campus</b> Top 10 mistakes in antibacterial development	<b>Spotlight on Switzerland</b>	<b>Expert campus</b> Focus TB diagnostics	<b>SME campus (Part I)</b> Focus on therapeutics  <b>SME campus (Part II)</b> Focus on diagnostics	<b>Expert campus</b> Diagnostics in clinical trial settings
Afternoon agenda >> digital AMR conference WEEK					
One topic spotlight each day	<b>Lessons learned from COVID-19</b>	<b>Business Mo- dels &amp; Policy Incentives</b>	<b>Global Markets</b>	<b>Financing &amp; Investing</b>	<b>Outlook &amp; Roadmap</b>
13:30–15:00 CEST	<b>Opening session</b> Infectious diseases in the global spotlight: Why COVID-19 and AMR are interlinked, and which impact it has on combat- ting AMR	<b>Business models</b> The AMR company of the future – Which route to success	<b>Global markets</b> Why AMR stake- holders need a global perspec- tive, and which impact it has on companies	<b>Financing resistance</b> Why new investors are urgently needed and where they come from	<b>Clinical trials</b> Why global net- works are crucial to speed up late stage clinical development
15:15–16:15 CEST	<b>Diagnostics</b> Why diag- nostics are a gamechanger to control a pan- demic and what this means for combatting AMR	<b>AMR pull incentives</b> Will COVID-19 finally speed up the race towards implementation?	<b>SME business approach</b> How to de- velop strategic decisions in a challenging and global AMR market	<b>Spotlight on UK</b> The Investor Year of Action on AMR	<b>Closing session</b> The future of AMR: How a new post-COVID-19 policy roadmap could look like
16:30–17:30 CEST	<b>One Health</b> Why it's more important than ever to think cross-sectoral	<b>Diagnostics</b> Do we need a novel global reimbursement scheme?	<b>Regulatory perspective</b> Will COVID-19 help establish a new fast track process for anti- biotic clinical trials & approvals?	<b>Behind the scenes</b> The Investor Year of Action on AMR	<b>Closing session</b> Investors' town- hall meeting
17:45–18:30 CEST		<b>Science collaboration</b> Why a strong academic net- work supports AMR companies			
Evening agenda >> Meet-ups					
19:30–20:30 CEST	<b>Evening meet-up</b> TBA		<b>Evening meet-up</b> TBA		